$22.45
1.45% yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US45249V1070
Symbol
ELVN
Sector
Industry

Imara Inc Stock price

$22.45
+2.85 14.51% 1M
+0.38 1.72% 6M
-0.05 0.22% YTD
-1.61 6.69% 1Y
+17.81 383.84% 3Y
-65.95 74.60% 5Y
-37.55 62.58% 10Y
-37.55 62.58% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.33 1.45%
ISIN
US45249V1070
Symbol
ELVN
Sector
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.0b
Net debt
positive
Cash
$289.6m
Shares outstanding
49.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 181,843.5
EV/Sales
- | 142,084.1
EV/FCF
negative
P/B
4.6
Financial Health
Equity Ratio
95.1%
Return on Equity
-28.7%
ROCE
-38.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $7.3k
EBITDA
$-110.0m | $-138.4m
EBIT
$-110.3m | $-136.6m
Net Income
$-94.8m | $-106.2m
Free Cash Flow
$-74.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-18.5% | -32.8%
EBIT
-18.4% | -30.6%
Net Income
-19.1% | -19.3%
Free Cash Flow
-15.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,900,462.2%
EBIT
-
Net
- | -1,457,635.0%
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-1.5
Short interest
21.1%
Employees
62
Rev per Employee
$0.0
Show more

Is Imara Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Imara Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Imara Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Imara Inc forecast:

Buy
93%
Hold
7%

Financial data from Imara Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 25 25
20% 20%
-
- Research and Development Expense 86 86
18% 18%
-
-110 -110
18% 18%
-
- Depreciation and Amortization 0.31 0.31
0% 0%
-
EBIT (Operating Income) EBIT -110 -110
18% 18%
-
Net Profit -95 -95
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Imara Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Imara Inc Stock News

Neutral
PRNewsWire
26 days ago
BOULDER, Colo. , June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' opt...
Neutral
PRNewsWire
29 days ago
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 pe...
Neutral
PRNewsWire
29 days ago
BOULDER, Colo. , June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so c...
More Imara Inc News

Company Profile

Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Samuel Kintz
Employees 62
Founded 2019
Website www.enliventherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today